ApicHope released its performance for the first three quarters, with a net loss attributable to the parent company of 136 million yuanZhitong·Oct 29, 2025 at 09:42 AM300723+4.13%
ApicHope: The latest clinical results of the innovative drug deuterated benzbromarone for the treatment of gout stones were released at ACR 2025Zhitong·Oct 29, 2025 at 03:39 AM300723+4.13%
ApicHope: Subsidiary's innovative drug APH03621 tablets approved for clinical trialsZhitong·Oct 24, 2025 at 03:10 AM300723+4.13%
ApicHope's subsidiary obtains registration certificate for Methanesulfonic acid new strychnine injectionZhitong·Oct 17, 2025 at 02:58 AM300723+4.13%
ApicHope: Fucanglin granules approved for clinical trialsZhitong·Sep 22, 2025 at 06:45 AM300723+4.13%
ApicHope's subsidiary has received the approval notice for the supplementary application of Oseltamivir Phosphate CapsulesZhitong·Sep 18, 2025 at 10:52 PM300723+4.13%
Innovative drug concept stocks rose in early trading, with Beigene up over 6%Zhitong·Sep 8, 2025 at 08:48 PM688180+2.15%01877+0.22%
ApicHope's subsidiary has obtained the registration certificate for injectable isavuconazoleZhitong·Sep 1, 2025 at 05:04 AM300723+4.13%
ApicHope: Wholly-owned subsidiary obtains registration certificate for escitalopram oxalate dropsZhitong·Aug 25, 2025 at 05:18 AM300723+4.13%
ApicHope: Gout innovative drug AR882 completes enrollment of all subjects in global Phase III clinical trialZhitong·Aug 21, 2025 at 04:16 AM300723+4.13%
ApicHope released its performance for the first half of the year, turning from profit to a loss of 73.5422 million yuanZhitong·Aug 21, 2025 at 03:20 AM300723+4.13%
Caitong Securities: Multiple new innovative drugs have emerged in the field of gout, focusing on companies related to uric acid reduction and acute phase relief treatmentZhitong·Aug 11, 2025 at 01:26 AM688302+2.44%000513+0.39%
Large orders frequently appear in the AI pharmaceutical field, and high-growth concept stocks are scarceZhitong·Aug 6, 2025 at 12:42 AM300723+4.13%688202+2.36%
